01.28.13
A new study found that supplementation with Lonza’s proprietary immune support ingredient ResistAid was associated with a statistically significant reduction (-23%) of the number of cold episodes in comparison with placebo. In this new multi-center, placebo-controlled, double-blind, randomized clinical trial, researchers measured the effect of supplementation with ResistAid larch arabinogalactan on common cold episodes. In the study, 199 healthy adults aged 18-70 with a self-reported rate of cold incidences of at least three in the prior six months were divided into two groups, taking either a daily larch arabinogalactan supplement of 4.5 grams or a placebo for 12 weeks. The participants documented each common cold episode and rated 10 predefined infection symptoms on a four-point rating scale during infection period, resulting in an infection score. In addition to three prescheduled study visits, medical doctors confirmed each common cold episode. Researchers found that the percentage of study days that participants did not suffer from any cold symptoms was significantly higher in the group taking ResistAid (91.2%) compared to the placebo group (88.5%). For further information:
http://informahealthcare.com/doi/abs/10.1185/03007995.2013.765837
http://informahealthcare.com/doi/abs/10.1185/03007995.2013.765837
